Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 5/20 | 0.55 |
| ▸ | HTR1B | P28222 | 4/20 | 0.55 |
| ▸ | CFB | P00751 | 5/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584946 | 0.87 | HTR1D (0.52) | HTR1DHTR1BCFBADRA2CADRA1A | |
| SCHEMBL7028929 | 0.80 | ADRA2A (0.46) | HTR1DHTR1BCFBADRA2CADRA1A | |
| Povafonidine SCHEMBL6581181 | 0.77 | ADRA2A (0.67) | HTR1DADRA2CADRA1AADRA2AADRA2B | |
| SCHEMBL6581982 | 0.77 | HTR1D (0.54) | HTR1DHTR1BCFBADRA2CADRA1A | |
| Povafonidine SCHEMBL8927783 | 0.76 | ADRA2A (0.66) | HTR1DADRA2CADRA1AADRA2AADRA2B | |
| SCHEMBL7086855 | 0.76 | HTR1D (0.48) | HTR1DHTR1BCFBADRA2CADRA1A | |
| SCHEMBL7027287 | 0.75 | ADRA2A (0.50) | HTR1DHTR1BCFBADRA2CADRA1A | |
| SCHEMBL6579623 | 0.74 | HTR1D (0.51) | HTR1DHTR1BCFBADRA2CADRA1A | |
| SCHEMBL8926989 | 0.74 | ADRA2A (0.52) | HTR1DHTR1BCFBADRA2CADRA1A | |
| SCHEMBL11187565 | 0.74 | HTR1D (0.76) | HTR1DHTR1BCFBADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975627-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1998046595-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | claimed |
| EP-1037887-B1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | PROCTER & GAMBLE (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-6486190-B1 | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability | THE PROCTER & GAMBLE COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| EP-1037887-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-0975627-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998046595-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | HTR1D 150/4885HTR1B 61/4885CFB 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.